Your browser is no longer supported. Please, upgrade your browser.
ALXN Alexion Pharmaceuticals, Inc. daily Stock Chart
Alexion Pharmaceuticals, Inc.
IndexS&P 500 P/E103.35 EPS (ttm)1.11 Insider Own0.10% Shs Outstand222.70M Perf Week3.33%
Market Cap25.53B Forward P/E13.18 EPS next Y8.70 Insider Trans-2.56% Shs Float222.68M Perf Month4.65%
Income251.80M PEG5.76 EPS next Q1.82 Inst Own97.50% Short Float1.67% Perf Quarter-10.24%
Sales3.91B P/S6.52 EPS this Y23.50% Inst Trans0.19% Short Ratio2.12 Perf Half Y-15.50%
Book/sh41.14 P/B2.79 EPS next Y14.31% ROA1.10% Target Price164.35 Perf Year-6.14%
Cash/sh6.89 P/C16.63 EPS next 5Y17.95% ROE1.70% 52W Range92.56 - 140.77 Perf YTD17.73%
Dividend- P/FCF74.79 EPS past 5Y11.10% ROI4.70% 52W High-18.58% Beta1.44
Dividend %- Quick Ratio2.70 Sales past 5Y25.60% Gross Margin89.20% 52W Low23.83% ATR4.39
Employees2525 Current Ratio3.20 Sales Q/Q19.50% Oper. Margin8.60% RSI (14)61.42 Volatility3.17% 4.29%
OptionableYes Debt/Eq0.35 EPS Q/Q343.90% Profit Margin3.90% Rel Volume1.07 Prev Close111.70
ShortableYes LT Debt/Eq0.32 EarningsFeb 04 BMO Payout0.00% Avg Volume1.75M Price114.62
Recom1.80 SMA2010.59% SMA501.41% SMA200-4.10% Volume1,861,015 Change2.61%
Aug-07-18Downgrade Stifel Buy → Hold $154 → $130
Feb-05-18Upgrade Evercore ISI In-line → Outperform
Jan-18-18Resumed Credit Suisse Outperform $147
Jan-04-18Downgrade Raymond James Strong Buy → Outperform
Dec-18-17Upgrade Robert W. Baird Neutral → Outperform $150
Oct-23-17Resumed Piper Jaffray Overweight $170
Sep-15-17Initiated RBC Capital Mkts Outperform $161
Sep-13-17Reiterated Leerink Partners Outperform $170 → $182
Sep-13-17Reiterated Deutsche Bank Buy $153 → $158
Sep-05-17Upgrade JP Morgan Neutral → Overweight
Aug-17-17Initiated Evercore ISI In-line $137
Jul-28-17Upgrade Oppenheimer Perform → Outperform
May-25-17Upgrade Morgan Stanley Equal-Weight → Overweight
May-23-17Downgrade JP Morgan Overweight → Neutral
Mar-30-17Initiated UBS Buy $138
Mar-02-17Initiated Instinet Buy $148
Feb-17-17Reiterated RBC Capital Mkts Outperform $187 → $177
Dec-22-16Reiterated RBC Capital Mkts Outperform $188 → $187
Dec-15-16Initiated Oppenheimer Perform
Dec-13-16Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-11-19 10:59AM  Why Sarepta Therapeutics Stock Is Starting to Shine Again InvestorPlace
10:20AM  Estimating The Fair Value Of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Simply Wall St.
Jan-10-19 08:01AM  Three tech, three biotech companies that are top takeover targets in 2019 MarketWatch
Jan-08-19 01:23PM  Edited Transcript of ALXN earnings conference call or presentation 24-Oct-18 12:00pm GMT Thomson Reuters StreetEvents
09:07AM  Why Alexion Pharmaceuticals Stock Fell 21% in December Motley Fool
08:56AM  4 Biotechs That Are Potential Buyouts Post Celgene Deal Zacks
Jan-07-19 07:30AM  Alexion to Report Fourth Quarter and Full Year 2018 Results on Monday, February 4, 2019 Business Wire
Jan-02-19 04:30PM  Alexion to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-27-18 06:21PM  Alexion's (ALXN) Soliris Drives Growth Amid Pricing Pressure Zacks
Dec-24-18 09:26AM  Alexion's Ultomiris Gets Early FDA Nod for Rare Blood Disorder Zacks
08:59AM  Acorda Gets FDA Approval for Parkinson's Disease Drug Inbrija Zacks
Dec-21-18 04:30PM  Alexion to Present at the Goldman Sachs 11th Annual Healthcare CEO Conference Business Wire -6.51%
04:25PM  'Santa Comes Early' As This Biotech Stock Grabs Its Fourth Approval Investor's Business Daily
11:23AM  Alexion Receives Early FDA Approval for ULTOMIRIS (Ravulizumab-cwvz) in Adults with Paroxysmal Nocturnal Hemoglobinuria (PNH) Business Wire
10:50AM  U.S. FDA approves Alexion Pharma's rare blood disorder drug Reuters
10:27AM  U.S. FDA approves Alexion Pharma's blood disorder drug Reuters
09:19AM  Agenus' Stock Up 23% on Immuno-Oncology Deal With Gilead Zacks
08:49AM  Allakos (ALLK) Catches Eye: Stock Jumps 6.5% Zacks
Dec-20-18 06:48AM  Alexion Pharmaceuticals Enters Oversold Territory Zacks
Dec-19-18 09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
Dec-18-18 05:32PM  Achillion Reports Positive Interim Data on Factor D Inhibitors Zacks
03:02PM  Why Achillion Pharmaceuticals Is Cratering Again Today Motley Fool
Dec-17-18 07:00AM  Report finds growing pains for rare disease drugs, but local biotechs buck trend American City Business Journals
Dec-14-18 12:02PM  Future HQ of Alexion, PTC sells for $455M to Norges Bank, American Realty American City Business Journals
10:25AM  AMAG to Acquire Ciraparantag Maker Perosphere Pharmaceuticals Zacks
Dec-12-18 03:17AM  The Zacks Analyst Blog Highlights: Gilead Sciences, Alexion Pharmaceuticals, Regeneron Pharmaceutical and Biogen Zacks
Dec-11-18 09:00AM  4 Biotech Stocks Investors Can Add to Their Portfolio in 2019 Zacks
08:52AM  Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher Zacks
Dec-10-18 08:45AM  Clovis Oncology (CLVS) in Focus: Stock Moves 6.9% Higher Zacks
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
05:05AM  Should You Avoid Alexion Pharmaceuticals, Inc. (ALXN)? Insider Monkey
Dec-05-18 09:49AM  Inovio (INO) to Receive Milestone Payment From AstraZeneca Zacks
08:46AM  UNITY (UBX) Soars: Stock Adds 5.1% in Session Zacks
08:41AM  Should You Get Rid of Acadia Healthcare (ACHC) Now? Zacks
Dec-04-18 04:34PM  Amgen's BiTE Immunotherapies Show Promise in Early Studies Zacks
08:13AM  Global Blood Therapeutics' Voxelotor on Faster Approval Path Zacks
Dec-03-18 02:32PM  Comprehensive Positive Phase 3 Data for Alexions ALXN1210 in Patients with Paroxysmal Nocturnal Hemoglobinuria Presented at American Society of Hematology (ASH) Annual Meeting and Published in Blood Business Wire
09:41AM  FDA Committee to Review Amgen's (AMGN) Osteoporosis Candidate Zacks
08:44AM  Fate Therapeutics (FATE) Jumps: Stock Rises 8.9% Zacks
Nov-30-18 08:39AM  Why Immunomedics (IMMU) Could Be Positioned for a Slump Zacks
Nov-28-18 10:22AM  Aileron Inks Collaboration Deal With Pfizer for Cancer Combo Zacks
Nov-27-18 10:44AM  Eyenovia Initiates Phase III Study for Mydriasis Candidate Zacks
08:37AM  Rocket Pharmaceuticals (RCKT) in Focus: Stock Moves 7.2% Higher Zacks
Nov-26-18 02:40PM  Should You Be Worried About Alexion Pharmaceuticals Incs (NASDAQ:ALXN) 1.7% Return On Equity? Simply Wall St.
08:44AM  Keryx (KERX) Looks Good: Stock Adds 7.2% in Session Zacks
Nov-21-18 03:20PM  Health Care Stocks Help This Fund Offset Tech Stocks' Dive Investor's Business Daily
Nov-20-18 04:30PM  Alexion to Present at the Evercore ISI Healthcare Conference Business Wire
04:25PM  IBD Stock Of The Day Breezes Toward Breakout On New Inhaler Uses Investor's Business Daily
09:10AM  Emergent's (EBS) Zika Vaccine Candidate Meets Study Endpoint Zacks
08:37AM  Fortress Biotech (FBIO) in Focus: Stock Moves 6.5% Higher Zacks
Nov-19-18 09:43AM  Amgen's Blincyto Gets Positive CHMP Opinion for Line Extension Zacks
08:41AM  Seattle Genetics (SGEN) Looks Good: Stock Adds 5.6% in Session Zacks
Nov-15-18 08:31AM  Looking for a Growth Stock? Why It is Time to Focus on Alexion Pharmaceuticals (ALXN) Zacks
Nov-12-18 10:50AM  AVEO Pharmaceuticals (AVEO) Q3 Earnings & Revenues Top Mark Zacks
Nov-08-18 11:11AM  Alexion Pharmaceuticals Dropped 19.4% in October, but the Business Remains Strong Motley Fool
Nov-07-18 04:30PM  Alexion to Present at Credit Suisses 27th Annual Healthcare Conference Business Wire
Nov-06-18 09:30AM  Is Alexion Pharmaceuticals (ALXN) Stock Outpacing Its Medical Peers This Year? Zacks
Nov-02-18 11:05AM  Alexion Completes Acquisition of Syntimmune Business Wire
08:15AM  Report: Developing Opportunities within General Electric, Arch Capital Group, China Petroleum & Chemical, Alexion Pharmaceuticals, GAIN Capital, and Sony Future Expectations, Projections Moving into 2018 GlobeNewswire
08:00AM  Today's Research Reports on Trending Tickers: Alexion Pharmaceuticals and OncoSec Medical ACCESSWIRE
Nov-01-18 03:34PM  Biotech ETFs in Focus on String of Q3 Earnings Beat Zacks +6.81%
10:23AM  Alexion Announces Upcoming Data Presentations at American Society of Hematology Annual Meeting Business Wire
Oct-31-18 02:08PM  Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q3, DRNA Soars on LLY Deal Zacks
05:19AM  Alexion Pharmaceuticals Sees Hammer Chart Pattern: Time to Buy? Zacks
Oct-24-18 11:28PM  Alexion Pharmaceuticals Inc (ALXN) Q3 2018 Earnings Conference Call Transcript Motley Fool -9.76%
04:41PM  Big Cap 20 Biotech Stock Dives On Mixed Third-Quarter Revenue Investor's Business Daily
10:46AM  Alexion enters RNA gene-silencing field with $637M Dicerna deal American City Business Journals
08:40AM  [$$] Alexion 3Q Profit Up, Boosts Revenue Guidance The Wall Street Journal
08:00AM  Alexion Pharmaceuticals (ALXN) Tops Q3 Earnings Estimates Zacks
07:49AM  Alexion stock rises 3% on Q3 beats, upbeat 2018 guidance MarketWatch
06:55AM  Alexion: 3Q Earnings Snapshot Associated Press
06:35AM  Alexion Reports Third Quarter 2018 Results Business Wire
06:30AM  Alexion and Dicerna Announce Collaboration to Discover and Develop RNAi Therapies for Complement-Mediated Diseases Business Wire
Oct-23-18 09:31AM  Biotech Stocks Earnings Lineup for Oct 24: VRTX, ALXN & SRPT Zacks
Oct-22-18 04:40PM  Alexion (ALXN) to Report Q3 Earnings: What's in the Cards? Zacks
Oct-19-18 09:04PM  Berkshire Hathaway Stock Looks Cheap by Warren Buffetts Measure
Oct-17-18 10:32AM  Alexion Pharmaceuticals (ALXN) Q3 Earnings Preview: What to Know Ahead of the Release Zacks
Oct-11-18 09:00AM  Investor Expectations to Drive Momentum within Materion, Iridium Communications, Natural Health Trends, Revance Therapeutics, Baxter International, and Alexion Pharmaceuticals Discovering Underlying Factors of Influence GlobeNewswire
Oct-10-18 10:10AM  Why Alexion (ALXN) is Poised to Beat Earnings Estimates Again Zacks -5.05%
Oct-04-18 04:30PM  Alexion to Report Third Quarter 2018 Results on Wednesday, October 24, 2018 Business Wire
Oct-03-18 10:54AM  Biotech Stock Roundup: ALXN on Acquisition Spree, FDA Nod for REGN, AMGN Drugs Zacks
Oct-01-18 10:28AM  5 Best Biotech Stocks to Buy In October Zacks
Sep-27-18 10:38AM  Alexion (ALXN) to Acquire Biotech Syntimmune for $1.2 Billion Zacks
10:19AM  Company News For Sep 27, 2018 Zacks
08:00AM  Todays Research Reports on Stocks to Watch: Aldeyra Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Sep-26-18 05:39PM  The Dow Cant Handle the Feds Truth +5.13%
04:19PM  Here's Why The Stock Market Sold Off After The Fed Meeting Investor's Business Daily
03:59PM  Stock News Today: Biotechs Help Nasdaq 100 To Day Of Outperformance Investor's Business Daily
03:56PM  Deals of the day-Mergers and acquisitions Reuters
12:32PM  Alexion to acquire Boston startup Syntimmune for up to $1.2B American City Business Journals
08:26AM  Biotech Stock Roundup: ALXN Soliris Successful, Respite For Sarepta, AMRN Soars Zacks
07:09AM  Alexion to buy biotech firm Syntimmune for up to $1.2 bln Reuters
07:02AM  [$$] Alexion Pharmaceuticals to Buy Syntimmune for Up to $1.2 Billion The Wall Street Journal
06:51AM  Alexion Pharmaceuticals to buy Syntimmune for up to $1.2 billion, including potential milestone payments MarketWatch
06:42AM  Alexion to buy biotech firm Syntimmune for up to $1.2 bln Reuters
06:30AM  Alexion to Acquire Syntimmune Business Wire
Sep-25-18 06:05PM  Alexion's Soliris Successful in Phase III Study for NMOSD Zacks
04:30PM  Alexion to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology Business Wire
08:50AM  Alexion Pharmaceuticals (ALXN) Surges: Stock Moves 5.3% Higher Zacks
08:00AM  Today's Research Reports on Trending Tickers: Akcea Therapeutics and Alexion Pharmaceuticals ACCESSWIRE
Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products; and collaboration with Dicerna Pharmaceuticals, Inc. to discover and develop RNAi therapies for complement-mediated diseases. The company was founded in 1992 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HANTSON LUDWIGCEODec 31Sale95.853,244310,937150,696Jan 03 06:07 PM
Franchini Indrani LallEVP, Chief Compliance OfficerNov 28Sale118.132,605307,72929,304Nov 30 06:15 PM
Clancy Paul JEVP, Chief Financial OfficerJul 10Sale131.115,241687,14893,309Jul 12 05:23 PM
Franchini Indrani LallEVP, Chief Compliance OfficerJun 08Sale118.531,466173,76531,909Jun 12 04:52 PM
Goff BrianEVP & Chief Commercial OfficerJun 08Sale118.531,645194,98236,257Jun 12 04:51 PM
LAW ANNE-MARIEEVP and CHROJun 08Sale118.531,862220,70329,450Jun 12 04:51 PM
ORLOFF JOHN JEVP, Research & DevelopmentJun 08Sale118.532,115250,69131,790Jun 12 04:51 PM
COUGHLIN CHRISTOPHER JDirectorApr 30Buy120.7910,0001,207,90026,333May 02 05:42 PM
Wagner Heidi LSVP, Global Government AffairsFeb 28Sale118.6145453,84949,140Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 28Sale118.6168681,36642,787Mar 01 05:25 PM
Wagner Heidi LSVP, Global Government AffairsFeb 27Sale120.7224429,45649,594Mar 01 05:25 PM
O'Neill JulieEVP. Global OperationsFeb 27Sale120.72939113,35643,473Mar 01 05:25 PM
Goff BrianEVP & Chief Commercial OfficerFeb 08Sale116.311,651192,02828,962Feb 08 07:17 PM
Moriarty John BEVP & General CounselFeb 08Sale115.703,363389,09974,537Feb 08 07:16 PM
O'Neill JulieEVP. Global OperationsFeb 08Sale116.314,787556,77644,412Feb 08 07:16 PM
Franchini Indrani LallEVP, Chief Compliance OfficerFeb 08Sale116.311,459169,69625,031Feb 08 07:16 PM
Clancy Paul JEVP, Chief Financial OfficerFeb 08Sale116.316,079707,04889,014Feb 08 07:17 PM
Wagner Heidi LSVP, Global Government AffairsFeb 08Sale116.311,774206,33449,838Feb 08 07:17 PM
HANTSON LUDWIGCEOFeb 08Sale116.3113,2451,540,526118,180Feb 08 07:16 PM
Wagner Heidi LSVP, Global Government AffairsFeb 05Sale117.2665576,80532,635Feb 07 06:36 PM
O'Neill JulieEVP. Global OperationsFeb 05Sale117.262,119248,47420,210Feb 07 06:35 PM
Moriarty John BEVP & General CounselFeb 05Sale117.261,261147,86549,911Feb 07 06:35 PM